A beleaguered class of epigenetic modulators continues to struggle for oncology success, but new insights into their mechanisms in cancer may yet offer hope.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma
Journal of Experimental & Clinical Cancer Research Open Access 02 December 2021
-
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
Journal of Hematology & Oncology Open Access 27 July 2020
-
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
Clinical Epigenetics Open Access 07 October 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
30 April 2015
Table 1 on page 226 described mocetinostat as an inhibitor of class I histone deacetylases (HDACs). It is also an inhibitor of HDAC11, which is in class IV. This has been corrected in the online version.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Guha, M. HDAC inhibitors still need a home run, despite recent approval. Nat Rev Drug Discov 14, 225–226 (2015). https://doi.org/10.1038/nrd4583
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4583
This article is cited by
-
Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents
Naunyn-Schmiedeberg's Archives of Pharmacology (2024)
-
Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma
Journal of Experimental & Clinical Cancer Research (2021)
-
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
Journal of Hematology & Oncology (2020)
-
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
Clinical Epigenetics (2019)
-
Genome-scale network model of metabolism and histone acetylation reveals metabolic dependencies of histone deacetylase inhibitors
Genome Biology (2019)
